Background Mutations in THAP1 were recently identifi ed as the cause of DYT6 primary dystonia; a founder mutation was detected in Amish-Mennonite families, and a diff erent mutation was identifi ed in another family of European descent. To assess more broadly the role of this gene, we screened for mutations in families that included one family member who had early-onset, non-focal primary dystonia.
Introduction
The clinical spectrum of primary dystonia is wide, ranging from childhood-onset disease that often generalises, to adult-onset, localised contractions that commonly aff ect the cervical or cranial muscles. From the earliest descriptions of dystonia, more than 100 years ago, genetic causes were suspected, particularly in individuals who had early onset. 1 Over the past 20 years, fi ve loci (DYT1, DYT6, DYT7, DYT13, and DYT17) have been mapped by genetic linkage in families with primary, pure forms of dystonia; however, the genes for only two, DYT1 and DYT6, have been identifi ed, and the gene for DYT6 was identifi ed only recently.
2-4 DYT1 is a major cause of early limb-onset disease, 5, 6 whereas DYT6, similar to other mapped loci, 7, 8 was thought to be of limited importance and found in only Amish-Mennonite families who share a founder haplotype. 9, 10 Now that THAP1, the gene that encodes THAP1 (thanatos-associated protein [THAP] domaincontaining apoptosis-associated protein 1), has been identifi ed as the gene that is mutated in DYT6, its role can be directly assessed.
We found two diff erent heterozygous mutations in THAP1 in fi ve families. 4 Four of the fi ve families had the same fi ve base pair insertion/three base pair deletion, the same haplotype, and an Amish-Mennonite ancestry, indicating a founder mutation. Furthermore, all fi ve families had similar clinical features and a phenotype that was described as "mixed". 4, 9, 10 The term mixed was chosen because most, but not all, of the aff ected family members had clinical features that were intermediate yet distinct from those of early-onset, limb-predominant dystonia, which is associated with DYT1, and late-onset localised cervical and cranial dystonia, which constitutes the majority of primary dystonia. Similar to DYT1, the symptoms of DYT6 tend to begin early, and the dystonia usually spreads to involve multiple body regions. However, unlike DYT1, DYT6 is more likely to begin in cervical or cranial muscles. When DYT6 starts in the limbs it is much more likely to spread to cranial muscles, whereas disabling leg and gait abnormal ities are less common in DYT6 than they are in DYT1.
In addition to fi nding the Amish-Mennonite founder mutation in THAP1, we also discovered a unique missense mutation in one family that had clinical similarities to the Amish-Mennonite families. This family had European but not Amish-Mennonite, ancestry, which suggests that THAP1 might also be a cause of dystonia outside the Amish-Mennonite population. We now report screening for DYT6 in DYT1-negative families that were not of Amish-Mennonite ancestry but have family members with early-onset non-focal primary dystonia, a phenotype that is consistent with DYT6.
Methods

Participants
Participating families were identifi ed from a database that includes individuals recruited from the Movement Disorders Center at Beth Israel Medical Center, New York; Columbia-Presbyterian Medical Center, New York; Mount Sinai School of Medicine, New York; and through research advertisements. We identifi ed 37 multiplex families in which at least one member had childhood-onset or adolescence-onset (ie, before age 22 years) symptoms of dystonia with muscle involvement that was either segmental, multifocal, or generalised. Families without Amish-Mennonite ancestry were recruited, and we tried to assess all living family members who were aff ected by or had screened positive for dystonic symptoms. For all aff ected individuals, there were no clinical signs or laboratory fi ndings of secondary dystonia, and mutation screening for the DYT1 GAG deletion was negative. One of the 37 families (family S) was also included in our initial report identifying mutations in THAP1; 4 hence, 36 families were newly screened for mutations in THAP1. 104 aff ected family members in the 36 newly screened families had clinical information and DNA available for analyses. Family S and the four Amish-Mennonite families (M, C, R, and W) were described in the previous report, and are included here as a separate group to describe more fully the phenotype associated with mutations in THAP1 and for phenotype-genotype analysis.
Of the 104 aff ected family members, 86 had in-person or videotaped examinations and four had video examinations and available records. Each of the 14 remaining individuals was examined by a collaborating neurologist, and clinical information about age at onset, the muscles initially aff ected, and progression were obtained from medical records and telephone interviews. Interviews, reviews of medical records, and examinations were done in accordance with published protocols to ensure that the diagnosis and distribution of the aff ected sites were consistent with primary dystonia. 11 Final clinical status was established through use of all available clinical information by two of the authors (SBB and RSP) who were blinded to an individual's DYT6 genotype. Age and site at onset were identifi ed by self report and by review of medical records.
All participants gave informed consent before their participation in this study, which was approved by the Beth Israel Medical Center, Columbia-Presbyterian Medical Center, and Mount Sinai School of Medicine review boards.
Procedures
Blood samples were collected and DNA was extracted by standard methods. Screening for the three base pair deletion in the DYT1 locus was done as previously described. 12 To investigate THAP1, we initially screened the index case from each of the 36 families. The three coding exons were fully sequenced, including the 5Ľ and 3Ľ untranslated regions (UTRs). To look for mutations at splice sites, at least 50 base pairs of the upstream and downstream intronic sequences that fl ank each exon were also sequenced. Standard polymerase chain reaction (PCR) amplifi cation was done; details of the Missense mutations. Each family number is followed by the corresponding mutation with the protein change in parenthesis. The sex of the individuals in the pedigees is not shown to protect the confi dentiality of the family members. Thus all individuals are represented by diamonds. Solid symbols denote aff ected individuals included in our analysis; half-fi lled symbols denote asymptomatic obligate carriers; a square inside a symbol denotes someone with a clear history of dystonia whose records or examination we were unable to obtain; the two individuals with grey symbols are phenocopies; a diagonal line through a symbol denotes deceased status; arrows indicate probands. Individuals D013, D020, and D022 from family 1 have been reported previously. 13 primers and conditions used are available on request. For exon one of THAP1, AccuPrime TM GC-rich DNA polymerase (Invitrogen, Carlsbad, CA, USA) was used in the amplifi cation. Standard dideoxy cycle sequencing was done on amplifi ed fragments. In 277 randomly acquired human DNA control samples from healthy white blood donors in the UK (Sigma-Aldrich, St Louis, MO, USA), the 5Ľ UTR and entire coding region of THAP1, including the splice sites, was sequenced. The Amish-Mennonite haplotype was identifi ed as previously described. 4 
Statistical analysis
The clinical features of all aff ected individuals from families with a DYT6 mutation were compared with individuals from mutation-negative families. Because more than one member of a family was included, we used generalised estimating equation models for dichotomous variables and a random eff ects model in generalised least squares regression for continuous or ordinal variables, to control for the non-independence of individuals within the same family. These models were used to compare age at onset, site of onset, fi nal distribution, sex, and fi nal sites involved. Analyses were done with STATA, version 10 (Stata, TX, USA). We also assessed the phenotypic diff erences between individuals with deletions or nonsense mutations in THAP1, which are predicted to produce truncated transcripts, and those with missense mutations.
Role of the funding source
The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and had fi nal responsibility for the decision to submit for publication.
Results
Of the 36 newly screened families, individuals in nine (25%) carried mutations; this group included 19 of 104 individuals (18%) aff ected with primary dystonia. Figure 1 shows the pedigrees and mutations in these families. Of note, a family member in family one and in family eight, who were rated to be aff ected, did not have the same mutation in THAP1 as the rest of the aff ected family members. Both of these individuals were men who had symptomatic brachial dystonia for 20 years but only when writing (writer's cramp that began at age 6 years and 34 years, respectively). These individuals were deemed to be phenocopies and were not included in the analysis of either genetic group of families.
Eight of the nine families carried novel mutations (fi gures 1 and 2). Seven of these eight mutations were in the region that encodes the DNA-binding domain of THAP1 and included one nonsense mutation, fi ve missense mutations (each of which resulted in the substitution of a residue that is highly conserved across species [fi gure 2]), and one small deletion that removed the start codon. The eighth mutation was a deletion of a single base pair that was predicted to result in a truncated protein; this would leave the DNA-binding domain intact but disrupt the nuclear-localisation signal. These mutations were not found in 554 chromosomes from white Europeans. The ninth family had the same insertion/deletion mutation and haplotype as that identifi ed in our AmishMennonite kindreds. This family was not aware of having an Amish-Mennonite background, but rather had mixed European ancestry. Ancestral countries of origin for the other eight families included: Ireland (n=3), Italy (n=2), Germany (n=2), and Russia (n=1). None reported Jewish ancestry. The 27 families in which mutations were not identifi ed included 85 individuals with dystonia. Self-reported ancestry included mixed European (n=13), Ashkenazi Jewish (n=6), Irish (n=3), African (n=2), Italian (n=2), and French Canadian (n=1).
The table summarises the clinical features of individuals with identifi ed mutations in THAP1. Among the newly described mutation-positive families, most individuals had childhood or adolescent onset, whereas three of 19 individuals had onset in adulthood (>21 years), at 25, 29, and 49 years, respectively. The fi rst symptoms were often in an arm, although fi ve of 15 individuals with arm onset reported simultaneous onset in other regions, including the other arm in three, a leg in one, and the other arm, neck, and tongue in another. Dystonia spread widely in most, with 12 of 19 aff ected individuals having generalised or multifocal distributions; even though one or both legs were involved in all, none required a wheelchair and most had only mild or moderate disability related to gait. Furthermore, all 12 aff ected individuals had cranial muscle involvement, which included the face, tongue, and larynx. When the group is considered overall, including the previously reported mutation-positive group, cranial 
Table:
Clinical presentation of groups positive and negative for the THAP1 mutation muscles were involved in 77% (37 of 48) and speech was aff ected in 67% (32 of 48). Although most of the aff ected individuals had widespread dystonia that aff ected the limbs, neck, and cranial muscles, fi ve had more restricted disease: four had writer's cramp and one had spasmodic dysphonia.
The oldest age at onset in the newly identifi ed group was greater than that previously reported for DYT6; however, the median age at onset was not diff erent between these groups (table). Clinical features were otherwise similar, except that the arm was more commonly the fi rst site to be aff ected in the newly identifi ed group.
Aff ected individuals from families without identifi ed mutations were signifi cantly older at onset than those in the mutation-positive group (table) despite the narrow inclusion criteria, which required at least one family member to have early-onset non-focal dystonia. The dystonia commonly began in the cervical muscles, unlike for those with mutations in THAP1 (60% . Despite these diff erences, several mutation-negative families had clinical features that were similar to those in mutation-positive families, including an early onset with spread to multiple regions and prominent cranial involvement that aff ected speech.
To assess the relation between genotype and clinical expression, we divided the 14 families that carried THAP1 mutations into two groups: those with predicted truncating mutations (eight families, including the original AmishMennonite kindred) and those with missense mutations (six families). We found no diff erences in age at onset, sites of onset, or fi nal distribution (data not shown).
Discussion
Mutations in THAP1, which cause DYT6 dystonia, are associated with a substantial proportion of familial early-onset primary dystonia; 25% of our 36 families had mutations in THAP1. Of the nine families with mutations, one family had the fi ve base pair insertion/three base pair deletion and haplotype of the Amish-Mennonite kindreds in whom DYT6 was fi rst mapped. The remaining eight families each had unique mutations in one of the three exons of THAP1 and were also from a diverse range of ancestries, although all were of European non-Jewish origin. There were no phenotypic diff erences that corresponded to mutation type; however, the identifi ed mutations either aff ected the DNA-binding domain or removed the nuclear-localisation signal of THAP1, which suggests that these domains are functionally important (fi gure 2). The DNA-binding domain is essential for the pro-apoptotic role that is associated with this protein: 15 THAP1 is a nuclear pro-apoptotic factor that interacts with prostate-apoptosis-response-4 (Par-4) and colocalises with it to promyelocytic leukaemia nuclear bodies. 15 We have proposed a role for mutated THAP1 in populations other than the Amish-Mennonite population, on the basis of one German family that had a diff erent missense mutation. 4 This family, similar to the Amish-Mennonite kindred, has a mixed phenotype; therefore, the fi rst step was to screen families from other populations with a consistent phenotype (ie, those with at least one member with early-onset and non-focal dystonia). Despite our clinical restrictions in defi ning the group of families for screening, we identifi ed diff erences between those with and those without mutations: mutation-positive individuals had an earlier-onset dystonia that had a greater tendency to generalise and more commonly involved brachial, facial, and oromandibular muscles than did the mutation-negative individuals. These diff erences are consistent with the previously reported characteristics of the mixed phenotype of DYT6.
9,10
Because we specifi cally excluded individuals with the DYT1 GAG deletion, we did not fully depict the range of early-onset dystonia and the distinct clinical features associated with THAP1 in this population compared with DYT1. For example, although many individuals with mutations in THAP1 had onset in childhood, and 90% began before age 30 years, more than 30% had onset after 18 years, which is a higher proportion than that reported for DYT1. 5, 16 Also, compared with DYT1, leg onset was less common in DYT6. 5 Perhaps the most distinctive characteristic of DYT6, which distinguishes it from DYT1, was the proportion of aff ected individuals with involvement of the cranial muscles, either at onset (29%) or later (77%); 12, 17 in most of these individuals, this produced disabling dysarthria or dysphonia. Finally, unlike DYT1, more women than men were aff ected. The higher proportion of aff ected women in families with DYT6 has been noted previously 10 but remains unexplained. The lifetime penetrance of DYT6 is estimated as 57-60%, and no sex diff erences have been identifi ed; 10 however, few male gene carriers were studied. The families reported here also included unaff ected mutation carriers, which is consistent with reduced penetrance (fi gure 1). Future systematic assessment of families with DYT6 should help to resolve whether a sex diff erence in penetrance can be shown.
Although we were able to confi rm an overall distinct clinical phenotype for DYT6, there are several caveats to our study. One important caveat is the recognition that the clinical expression of DYT6 is broad and overlaps with non-DYT6 dystonia subtypes. This applies to other subgroups of dystonia that have prominent speech involvement (eg, DYT4, DYT17, and DYT12) and the common phenotype of brachial and bi-brachial dystonia. Indeed, we identifi ed two family members in mutation-positive families who had writer's cramp but did not carry the family mutation. Writer's cramp is a particularly problematic phenotype for genetic studies, 18, 19 and the need for caution when classifying individuals as "aff ected" for gene mapping is reinforced by our study. Also, mutation analysis was restricted to sequence variants within the regions that were screened. Screening for other genetic changes, including exon deletions, multiplications, and variations in the intronic regions, might identify additional aff ected individuals and requires further study. Finally, we only assessed a population that is consistent with the initially described DYT6 phenotype; other dystonia populations, particularly sporadic and late-onset focal dystonias, were untested.
Future studies should help to clarify the role of mutations in THAP1 in dystonia and their pathogenic eff ects. On the basis of the mutations identifi ed, the DNA-binding and pro-apoptotic functions of THAP1 are implicated; transcription factors and apoptosis have not been associated with primary dystonia, although TAF1, the gene that causes X-linked dystonia parkinsonism, encodes the transcription factor TAF1. 20 Of further interest is the potential divergent and common eff ects of THAP1 and torsinA. TorsinA is the product of TOR1A, and mutations in this gene cause DYT1 dystonia. Mutations in the genes that encode these proteins lead to subtly diff erent clinical phenotypes. In addition, PET and MRI studies have shown that DYT6 "manifesting" gene carriers share metabolic 21 and anatomic 22 abnormalities with those who manifest DYT1, yet metabolic diff erences between DYT1 and DYT6 genotypes were also shown. This suggests that mutant torsinA and THAP1 have distinct pathogenic origins and might converge on key brain targets to produce a common motor phenotype. Understanding the function of THAP1 and investigating its potential interactions with torsinA should provide novel mechanistic clues and targets for therapy.
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